News
Exosome Diagnostics Announces Expansion of Scientific Advisory Board
NEW YORK (NY, USA) May 24, 2011 – Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, PhD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).
Dr. Carter is Professor and Chief of Neurosurgery at the University of California, San Diego Medical Center
(UCSD) and co-leads the clinical brain tumor program. He was recruited to UCSD in 2010 from Massachusetts
General Hospital and Harvard Medical School where he served on staff since 1992. Dr. Carter obtained his
M.D. and Ph.D. degrees at the Johns Hopkins University School of Medicine and Public Health respectively.
His post-doctoral training included residency in neurosurgery at Massachusetts General Hospital and
post-doctoral fellowships at the Whitehead Institute, Cambridge, MA and Children's Hospital, Boston.
http://neurosurgery.ucsd.edu/bob-s-carter-md-phd/
Dr. Cordon-Cardo is Vice Chairman of Pathology and Professor of Pathology and Urology at Columbia
University in addition to being Associate Director of Infrastructure at the Herbert Irving Comprehensive
Cancer Center. Dr. Cordon-Cardo obtained his M.D. from the Autonomous University of Barcelona, Spain, in
1980, and his Ph.D. in Cell Biology and Genetics from Cornell University Medical College in 1985. He has
pioneered the development and implementation of an oncologic molecular pathology discipline, and more
recently participated in the creation of the "systems pathology" platform. He is internationally recognized
for his studies on experimental pathology and molecular oncology, including analyses of multidrug resistance
and alterations of tumor suppressor genes in human cancer, mainly those deregulating cell cycle.
http://columbiaurology.org/about/researchfaculty/cordon-cardo.html
Dr. Flaherty is Director of Developmental Therapeutics at the Massachusettes General Hospital
Cancer Center and a Lecturer in the Department of Medicine at Harvard Medical School. He is also involved
in research programs in cutaneous oncology, melanoma, translational pharmacology and early therapeutic
trials. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in
cancer. In this context he focused on the development of response and predictive biomarkers to define the
mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.
He served as principal investigator for the first-in-human clinical trials of the first prospectively
developed selective BRAF inhibitors, RAF-265 and PLX403.
http://www.dfhcc.harvard.edu/membership/profile/member/1632/0/
Dr. Quackenbush is Professor of Computational Biology and Bioinformatics at the Dana-Faber Cancer Institute,
Harvard. Dr. Quackenbush completed a Ph.D. in theoretical physics followed by a two-year postdoctoral
position in experimental particle physics and phenomenology. Currently, Dr. Quackenbush is focused on
research projects that include the identification of expression fingerprints and genomic alterations that
are relevant to colon and breast tumor metastasis, the development of novel computational approaches for
the interpretation of large-scale datasets and methods for data integration to facilitate gene discovery.
http://www.hsph.harvard.edu/faculty/john-quackenbush/
About Exosome Diagnostics:
Exosome Diagnostics is a leading developer of biofluid based molecular diagnostic tests for use in
personalized medicine. Exosomes are shed into all biofluids, including blood, urine, and CSF, forming
a highly enriched source of intact, disease-specific nucleic acids. The Company’s proprietary exosome
technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene
transcripts and the expression of genes responsible for cancers and other diseases. The Company is
commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time
monitoring of disease. The Company maintains facilities in New York, NY, St. Paul, MN and Munich, Germany
and is backed by an international consortium of leading venture capitalists. For more information,
please visit www.exosomedx.com.
Contact:
Exosome Diagnostics
College Hill Life Sciences
Adam Michael, Gemma Howe
Exosome@collegehill.com
+44 20 7866 7861